A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease

The duration and nature of immunity generated in response to SARS-CoV-2 infection is unknown. Many public health responses and modeled scenarios for COVID-19 outbreaks caused by SARS-CoV-2 assume that infection results in an immune response that protects individuals from future infections or illness for some amount of time. The timescale of protection is a critical determinant of the future impact of the pathogen. The presence or absence of protective immunity due to infection or vaccination (when available) will affect future transmission and illness severity. The dynamics of immunity and nature of protection are relevant to discussions surrounding therapeutic use of convalescent sera as well as efforts to identify individuals with protective immunity. Here, we review the scientific literature on antibody immunity to coronaviruses, including SARS-CoV-2 as well as the related SARS-CoV-1, MERS-CoV and human endemic coronaviruses (HCoVs). We reviewed 1281 abstracts and identified 322 manuscripts relevant to 5 areas of focus: 1) antibody kinetics, 2) correlates of protection, 3) immunopathogenesis, 4) antigenic diversity and cross-reactivity, and 5) population seroprevalence. While studies of SARS-CoV-2 are necessary to determine immune responses to it, evidence from other coronaviruses can provide clues and guide future research.

[1]  Robert Fantina,et al.  Challenges and Pitfalls , 2021, Introducing Robotic Process Automation to Your Organization.

[2]  Rachel E. Baker,et al.  Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic , 2020, Science.

[3]  Zacharias E. Andreadakis,et al.  The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.

[4]  Xuetao Cao.  COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.

[5]  Bryan T Grenfell,et al.  Susceptible supply limits the role of climate in the COVID-19 pandemic , 2020, medRxiv.

[6]  C. Hillyer,et al.  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.

[7]  M. Lipsitch,et al.  Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure , 2020, The Journal of infectious diseases.

[8]  Guohong Deng,et al.  Viral Kinetics and Antibody Responses in Patients with COVID-19 , 2020, medRxiv.

[9]  M. Lipsitch,et al.  Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China , 2020, Nature Medicine.

[10]  Arturo Casadevall,et al.  The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.

[11]  R. Scheuermann,et al.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.

[12]  Yonatan H. Grad,et al.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.

[13]  Jessica T Davis,et al.  The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak , 2020, Science.

[14]  Yuntao Wu,et al.  Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools , 2020, Virologica Sinica.

[15]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[16]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[17]  G. Gorse,et al.  Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus‐associated illnesses , 2020, Journal of medical virology.

[18]  Yang Liu,et al.  Early dynamics of transmission and control of COVID-19: a mathematical modelling study , 2020, The Lancet Infectious Diseases.

[19]  A. Hassan,et al.  Seroprevalence of MERS-CoV in healthy adults in western Saudi Arabia, 2011–2016 , 2020, Journal of Infection and Public Health.

[20]  D. Cummings,et al.  Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions , 2020, medRxiv.

[21]  Wei Zhang,et al.  Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes , 2020, Emerging microbes & infections.

[22]  Zhènglì Shí,et al.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, bioRxiv.

[23]  D. Cummings,et al.  Impacts of Zika emergence in Latin America on endemic dengue transmission , 2019, Nature Communications.

[24]  B. Bosch,et al.  Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections , 2019, Emerging infectious diseases.

[25]  M. V. Van Kerkhove,et al.  Transmissibility of MERS-CoV Infection in Closed Setting, Riyadh, Saudi Arabia, 2015 , 2019, Emerging infectious diseases.

[26]  M. Killerby,et al.  Risk Factors for MERS-CoV Seropositivity among Animal Market and Slaughterhouse Workers, Abu Dhabi, United Arab Emirates, 2014–2017 , 2019, Emerging infectious diseases.

[27]  C. Midgley,et al.  Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia , 2019, Emerging infectious diseases.

[28]  A. Tamin,et al.  Development and Evaluation of a Multiplexed Immunoassay for Simultaneous Detection of Serum IgG Antibodies to Six Human Coronaviruses , 2019, Scientific Reports.

[29]  A. Tamin,et al.  Serologic Follow-up of Middle East Respiratory Syndrome Coronavirus Cases and Contacts—Abu Dhabi, United Arab Emirates , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[31]  P. T. Ten Eyck,et al.  High Prevalence of MERS-CoV Infection in Camel Workers in Saudi Arabia , 2018, mBio.

[32]  I. Jo,et al.  Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity , 2017, Diagnostic Microbiology and Infectious Disease.

[33]  Kyoung-Ho Song,et al.  MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015 , 2017, Emerging infectious diseases.

[34]  M. Koopmans,et al.  Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013–2014: A Case-Control Study , 2017, The Journal of infectious diseases.

[35]  Yufei Wang,et al.  Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants , 2016, Journal of Virology.

[36]  Christl A. Donnelly,et al.  Countering the Zika epidemic in Latin America , 2016, Science.

[37]  R. Bruzzone,et al.  Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. , 2016, Hong Kong medical journal = Xianggang yi xue za zhi.

[38]  S. Perlman,et al.  Antibody Response and Disease Severity in Healthcare Worker MERS Survivors , 2016, Emerging infectious diseases.

[39]  Serological Study of An Imported Case of Middle East Respiratory Syndrome and His Close Contacts in China, 2015 , 2016, Biomedical and Environmental Sciences.

[40]  M. Ravid,et al.  A Six-Year Follow-up Study , 2016 .

[41]  E. Lau,et al.  Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea , 2015, Emerging infectious diseases.

[42]  L. Ren,et al.  Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection , 2015, Journal of Infection.

[43]  Victor M Corman,et al.  Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study , 2015, The Lancet Infectious Diseases.

[44]  C. Tse,et al.  Global Spatio-temporal Patterns of Influenza in the Post-pandemic Era , 2014, Scientific Reports.

[45]  Winnie Tu.  The Burning Building , 2015 .

[46]  Christian Drosten,et al.  Evidence for camel-to-human transmission of MERS coronavirus. , 2014, The New England journal of medicine.

[47]  M. Koopmans,et al.  Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen , 2014, International Journal of Antimicrobial Agents.

[48]  Fu-Tong Liu,et al.  Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins , 2014, Biochemical and Biophysical Research Communications.

[49]  Christian Drosten,et al.  Serological assays for emerging coronaviruses: Challenges and pitfalls , 2014, Virus Research.

[50]  Lisa E. Gralinski,et al.  Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses , 2013, The Journal of infectious diseases.

[51]  Z. Memish,et al.  Investigation of Anti–Middle East Respiratory Syndrome Antibodies in Blood Donors and Slaughterhouse Workers in Jeddah and Makkah, Saudi Arabia, Fall 2012 , 2013, The Journal of infectious diseases.

[52]  J. Peiris,et al.  Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus , 2014, Virology Journal.

[53]  R. Lu,et al.  First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood , 2013, BMC Infectious Diseases.

[54]  E. Walsh,et al.  Clinical Impact of Human Coronaviruses 229E and OC43 Infection in Diverse Adult Populations , 2013, The Journal of infectious diseases.

[55]  Shibo Jiang,et al.  Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC , 2013, Journal of Infection.

[56]  Herman Tse,et al.  Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests , 2013, Journal of Infection.

[57]  M. Hou,et al.  Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot: Implications for the diagnosis of coronavirus infection , 2012, Journal of Virological Methods.

[58]  B. Prabhakar,et al.  Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing , 2012, PloS one.

[59]  F. Ibrahim,et al.  Potential cross-reactivity of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid (N)-based IgG ELISA assay for plasma samples from HIV-1 positive intravenous drug users (IDUs). , 2012, Acta medica Indonesiana.

[60]  T. Kuijpers,et al.  The dominance of human coronavirus OC43 and NL63 infections in infants , 2011, Journal of Clinical Virology.

[61]  J. Peiris,et al.  Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway , 2011, Journal of Virology.

[62]  Pavel Dedera,et al.  Mathematical Modelling of Study , 2011 .

[63]  Hong Yang,et al.  Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study , 2011, The Journal of Immunology.

[64]  P. Simmonds,et al.  Epidemiology and Clinical Presentations of the Four Human Coronaviruses 229E, HKU1, NL63, and OC43 Detected over 3 Years Using a Novel Multiplex Real-Time PCR Method , 2010 .

[65]  Shuying Wang,et al.  Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies , 2009, Molecular Immunology.

[66]  N Hens,et al.  Seventy-five years of estimating the force of infection from current status data , 2009, Epidemiology and Infection.

[67]  J. Crowe,et al.  The Pediatric Burden of Human Coronaviruses Evaluated for Twenty Years , 2009, The Pediatric infectious disease journal.

[68]  K. Yuen,et al.  Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus , 2009, Journal of Clinical Virology.

[69]  P. Wang,et al.  Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital , 2009, Scandinavian journal of infectious diseases.

[70]  Weijun Chen,et al.  The expression and antigenicity of a truncated spike-nucleocapsid fusion protein of severe acute respiratory syndrome-associated coronavirus , 2008, BMC Microbiology.

[71]  E. Severance,et al.  Development of a Nucleocapsid-Based Human Coronavirus Immunoassay and Estimates of Individuals Exposed to Coronavirus in a U.S. Metropolitan Population , 2008, Clinical and Vaccine Immunology.

[72]  A. Falsey,et al.  Long‐Term Care Facilities: A Cornucopia of Viral Pathogens , 2008, Journal of the American Geriatrics Society.

[73]  K. Pyrć,et al.  Human Coronavirus NL63 and 229E Seroconversion in Children , 2008, Journal of Clinical Microbiology.

[74]  Yun Cheng,et al.  Human LINE1 endonuclease domain as a putative target of SARS-associated autoantibodies involved in the pathogenesis of severe acute respiratory syndrome. , 2008, Chinese medical journal.

[75]  R. Baric,et al.  Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.

[76]  Y. Shao,et al.  A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses , 2008, Diagnostic Microbiology and Infectious Disease.

[77]  Ali Danesh,et al.  Human immunopathogenesis of severe acute respiratory syndrome (SARS) , 2007, Virus Research.

[78]  A. Vlasova,et al.  Two-Way Antigenic Cross-Reactivity between Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Group 1 Animal CoVs Is Mediated through an Antigenic Site in the N-Terminal Region of the SARS-CoV Nucleoprotein , 2007, Journal of Virology.

[79]  Xiaojie Guo,et al.  Seroepidemiology of group I human coronaviruses in children , 2007, Journal of Clinical Virology.

[80]  W. Cao,et al.  Disappearance of antibodies to SARS-associated coronavirus after recovery. , 2007, The New England journal of medicine.

[81]  D. Dimitrov,et al.  Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies , 2007, Proceedings of the National Academy of Sciences.

[82]  D. Ho,et al.  Natural Mutations in the Receptor Binding Domain of Spike Glycoprotein Determine the Reactivity of Cross-Neutralization between Palm Civet Coronavirus and Severe Acute Respiratory Syndrome Coronavirus , 2007, Journal of Virology.

[83]  J. A. Comer,et al.  Recombinant Protein-Based Assays for Detection of Antibodies to Severe Acute Respiratory Syndrome Coronavirus Spike and Nucleocapsid Proteins , 2007, Clinical and Vaccine Immunology.

[84]  Ze Chen,et al.  Children’s vaccines do not induce cross reactivity against SARS-CoV , 2006, Journal of Clinical Pathology.

[85]  J. Manson,et al.  Prospective Study of , 2007 .

[86]  M. Drebot,et al.  An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus. , 2006, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[87]  M. Han,et al.  Cross-Protection against a Human Enteric Coronavirus and a Virulent Bovine Enteric Coronavirus in Gnotobiotic Calves , 2006, Journal of Virology.

[88]  Shibo Jiang,et al.  Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein , 2006, The Journal of Immunology.

[89]  Wei Liu,et al.  Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome , 2006, The Journal of infectious diseases.

[90]  S. Perlman,et al.  Immunopathogenesis of coronavirus infections: implications for SARS , 2005, Nature Reviews Immunology.

[91]  Jeng-Min Chiou,et al.  Neutralizing Antibody Response and SARS Severity , 2005, Emerging infectious diseases.

[92]  P. Woo,et al.  Serological Responses in Patients with Severe Acute Respiratory Syndrome Coronavirus Infection and Cross-Reactivity with Human Coronaviruses 229E, OC43, and NL63 , 2005, Clinical Diagnostic Laboratory Immunology.

[93]  S. Au,et al.  Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11 , 2005, Biochemical and Biophysical Research Communications.

[94]  K. Tsao,et al.  False positive antibody results against human T‐cell lymphotropic virus in patients with severe acute respiratory syndrome , 2005, Journal of medical virology.

[95]  P. Liao,et al.  Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity , 2005, Clinical and experimental immunology.

[96]  Shibo Jiang,et al.  Identification of Immunodominant Epitopes on the Membrane Protein of the Severe Acute Respiratory Syndrome-Associated Coronavirus , 2005, Journal of Clinical Microbiology.

[97]  C. Fraser,et al.  Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups , 2005, Epidemiology and Infection.

[98]  S. Inoue,et al.  Evaluation of Inapparent Nosocomial Severe Acute Respiratory Syndrome Coronavirus Infection in Vietnam by Use of Highly Specific Recombinant Truncated Nucleocapsid Protein-Based Enzyme-Linked Immunosorbent Assay , 2005, Clinical Diagnostic Laboratory Immunology.

[99]  V. Cheng,et al.  Antigenic Cross-Reactivity between Severe Acute Respiratory Syndrome—Associated Coronavirus and Human Coronaviruses 229E and OC43 , 2005, The Journal of infectious diseases.

[100]  A. Carattoli,et al.  Recombinant protein‐based ELISA and immuno‐cytochemical assay for the diagnosis of SARS† , 2005, Journal of medical virology.

[101]  Zhihong Guo,et al.  B-Cell Responses in Patients Who Have Recovered from Severe Acute Respiratory Syndrome Target a Dominant Site in the S2 Domain of the Surface Spike Glycoprotein , 2005, Journal of Virology.

[102]  Kwanyee Leung,et al.  Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[103]  W. Ehrengut,et al.  A two year serological surveillance of coronavirus infections in Hamburg , 2005, Infection.

[104]  A. Bradburne.  Antigenic relationships amongst coronaviruses , 2005, Archiv für die gesamte Virusforschung.

[105]  P. Hsueh,et al.  Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS‐associated coronavirus , 2004, Clinical Microbiology and Infection.

[106]  B. Moss,et al.  Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[107]  Xinchun Chen,et al.  Serology of Severe Acute Respiratory Syndrome: Implications for Surveillance and Outcome , 2004, The Journal of infectious diseases.

[108]  Shiou-Hwei Yeh,et al.  Microbiologic Characteristics, Serologic Responses, and Clinical Manifestations in Severe Acute Respiratory Syndrome, Taiwan , 2003, Emerging infectious diseases.

[109]  Zhe Zhao,et al.  A Strategy for Searching Antigenic Regions in the SARS-CoV Spike Protein , 2003, Genomics, Proteomics & Bioinformatics.

[110]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[111]  E. Walsh,et al.  Rhinovirus and Coronavirus Infection-Associated Hospitalizations among Older Adults , 2002, The Journal of infectious diseases.

[112]  D. Tyrrell,et al.  The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.

[113]  D. Tyrrell,et al.  The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers , 1990, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[114]  A. Nisalak,et al.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.

[115]  J. Fox,et al.  RISES IN TITERS OF ANTIBODY TO HUMAN CORONA VIRUSES OC43 AND 229E IN SEATTLE FAMILIES DURING 1975–1979 , 1986, American journal of epidemiology.

[116]  C. Rosenfeld,et al.  Isolation and propagation of a human enteric coronavirus. , 1986, Science.

[117]  K. Callow.  Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection , 1985, Journal of Hygiene.

[118]  P. Saikku,et al.  Age‐specific prevalence of complement‐fixing antibodies to sixteen viral antigens: A computer analysis of 58,500 patients covering a period of eight years , 2005, Journal of medical virology.

[119]  S. Reed.  The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: Evidence of heterogeneity among 229E‐related strains , 2005, Journal of medical virology.

[120]  G. Gerna,et al.  Antigenic Relatedness of Human Enteric Coronavirus Strains to Human Coronavirus OC43: A Preliminary Report , 1984, The Journal of infectious diseases.

[121]  F. Scott,et al.  Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic fever☆ , 1981, Comparative Immunology, Microbiology and Infectious Diseases.

[122]  J. Gerdes,et al.  Coronavirus isolates SK and SD from multiple sclerosis patients are serologically related to murine coronaviruses A59 and JHM and human coronavirus OC43, but not to human coronavirus 229E , 1981, Journal of virology.

[123]  M. R. Macnaughton,et al.  Enzyme-linked immunosorbent assay for detection of antibody in volunteers experimentally infected with human coronavirus strain 229 E , 1980, Journal of clinical microbiology.

[124]  A. Salmi,et al.  OC43 strain‐related coronavirus antibodies in different age groups , 2005, Journal of medical virology.

[125]  H. S. Kaye,et al.  Antigenic Relationship between Human Coronavirus Strain DC 43 and Hemagglutinating Encephalomyelitis Virus Strain 67N of Swine: Antibody Responses in Human and Animal Sera , 1977, The Journal of infectious diseases.

[126]  A. Monto,et al.  The Tecumseh Study of Respiratory Illness. VI. Frequency of and Relationship between Outbreaks of Coronavims Infection , 1974, The Journal of infectious diseases.

[127]  H. S. Kaye,et al.  Detection of coronavirus 229E antibody by indirect hemagglutination. , 1972, Applied microbiology.

[128]  M. Beem,et al.  VIROLOGIC STUDIES OF ACUTE RESPIRATORY DISEASE IN YOUNG ADULTS , 1972, American journal of epidemiology.

[129]  A. Monto,et al.  Community-wide Outbreak of Infection with a 229E-like Coronavirus in Tecumseh, Michigan , 1970, The Journal of infectious diseases.

[130]  D. Tyrrell,et al.  Effects of a "new" human respiratory virus in volunteers. , 1967, British medical journal.

[131]  D. Tyrrell,et al.  Cultivation of a Novel Type of Common-cold Virus in Organ Cultures , 1965, British medical journal.

[132]  M. Sherman,et al.  A Preliminary Report , 1953 .